on Wednesday flagged promising late-stage demo success for its new Cagrilinitide obesity treatment method, as the Danish pharmaceutical huge seeks a next-generation alternate to its blockbuster Wegovy pounds-reduction drug.That said, Cagrilintide is still in Phase II/III trials. Though the early information is fascinating, it hasn't however been pe